Both companies said they have so far found no serious safety concerns and expect to seek US authorization this month for emergency use of the vaccine.
On Monday, Pfizer Inc said its experimental COVID-19 vaccine was more than 90% effective, a major victory in the fight against a pandemic that has killed more than a million people, battered the world’s economy and upended daily life, NDTV reported.
Pfizer and German partner BioNTech SE are the first drugmakers to release successful data from a large-scale clinical trial of a coronavirus vaccine. Both companies said they have so far found no serious safety concerns and expect to seek US authorization this month for emergency use of the vaccine.
Pfizer’s results, according to health experts, were positive for all COVID-19 vaccines currently in development since they show the shots are going after the right target and are a proof of concept that the disease can be halted with vaccination.
Albert Bourla, Pfizer’s chairman and chief executive, said: “Today is a great day for science and humanity.”
“We are reaching this critical milestone in our vaccine development program at a time when the world needs it most with infection rates setting new records, hospitals nearing over-capacity and economies struggling to reopen,” he further added.
If authorized, the number of doses of Pfizer’s vaccine will initially be limited and many questions remain, including how long the vaccine will provide protection.
Ugur Sahin, the BioNTech Chief Executive,
told Reuters he was optimistic the immunisation effect of the vaccine would last for a year although that was not certain yet.
“This news made me smile from ear to ear. It is a relief to see such positive results on this vaccine and bodes well for COVID-19 vaccines in general,” said Peter Horby, professor of emerging infectious diseases at the University of Oxford.